Myeloma - Biotech, Pharma and Life Science Channel
Myeloma is a malignant disease of the bone marrow. The features are an excess of abnormal malignant plasma cells in the bone marrow, lytic deposits on an X-ray and abnormal gammaglobulin in the serum.
Symptoms include tiredness and bone pain, and there may be pathological fractures in the bones.
Chemotherapy and possible local radiotherapy are treatment options.
Source; Adapted from Oxford Concise Medical Dictionary
Add the Myeloma News Channel to your RSS reader;
Follow the Myeloma Twitter feed;
News Articles
Study using Novel Biomarker Technology Indicates Potential Medical Utility in Discriminating Clinical Outcomes Eutropics Pharmaceuticals Inc. announced today that Eutropics an...
NORTH CHICAGO, Ill., May 15, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that data evaluating several investigational compounds in the company's oncology pipeline will be presented a...
Poster Presentation at 16th Annual Meeting of American Society of Gene & Cell Therapy Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTC QB: SNTI),...
BURLINGTON, Mass., May 14, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and E...
Senesco Announces $1.255 Million Equity Financing
Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTCQB: SNTI) announced today that it has entered into a securities purchase agreement with certain institutional i...
Grammy Nominated Comedian Jim Gaffigan Headlines Comedy Show and Donna Zaccaro Ullman Honored with Spirit of Hope Award On Tuesday evening over 700 guests from the Tri-State a...
Data Review Committee Approves Dose Escalation Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTC QB: SNTI) reported today that the Data Review Committee (DR...
—Funds from E-Race Cancer on Facebook to be Presented by Runner Don Wright at Team Continuum Annual Fundraising Event May 8— —Money Helps Cancer Patients Pay...
Patent Issued In China For EntreMed's Lead Drug Candidate ENMD-2076
ROCKVILLE, Md., May 6, 2013 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, today announc...
The Patients Equal Access Coalition Applauds a New Bill to Improve Access to Oral Cancer Drugs
The Patients Equal Access Coalition (PEAC) commends Congressman Brian Higgins (NY-26th District) on the introduction of the Cancer Drug Coverage Parity Act, H.R. 1801 on Ap...
Events
None
Companies
Eutropics Pharmaceuticals Inc.
Eutropics is addressing the need for improving the treatment of aggressive forms of leukemia, myeloma, lymphoma, and other cancers. The company is developing a novel diagnostic te...
The Multiple Myeloma Research Consortium
The Multiple Myeloma Research Consortium (MMRC) is a 509(a)3 non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myelo...
Multiple Myeloma Research Foundation (MMRF)
Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 38 percent, one of the lowest of all cancers. In 2010, mo...
The Leukemia & Lymphoma Society and Reliant Energy
The Leukemia & Lymphoma Society ® (LLS) is the worldâs largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkinâ...
Tensha Therapeutics is developing small molecule bromodomain inhibitors, a new class of epigenetic modulators of gene expression, to treat cancer and other serious disorders. The...
The Multiple Myeloma Research Consortium (MMRC)
Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 38 percent, one of the lowest of all cancers. In 2011, mo...
Multiple Myeloma Research Consortium
The Multiple Myeloma Research Consortium (MMRC) is a 509(a) 3 non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myel...
Multiple Myeloma Research Foundation
The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's dia...
The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society ® (LLS) is the worldâs largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkinâ...
The International Myeloma Foundation
Leading myeloma experts will discuss the latest treatment paradigms, coming out of ASH that could deliver the long-term survivors of the future, in a panel discussion moderated by...
Clinical Trials
RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Chemopro...
Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma
Evidence for the beneficial effects of bisphosphonates on bone resorption in multiple myeloma has been reported extensively, showing reductions in skeletal events and improvement of severa...
Phase III Randomized Trial of Thalidomide/Dexamethasone vs VAD.
This study compares the response rate, overall response rate and survival of patients with multiple myeloma when randomized to two regimens (thalidomide+Dexamethasone vs. Vincristine+Adria...
RATIONALE: Biological therapies, such as thalidomide and clarithromycin, may stimulate the immune system in different ways and stop cancer cells from growing. Thalidomide and clarithromyci...
Clinical Implication of Bone Marrow Perfusion Patterns Imaged by Dynamic MRI in Multiple Myeloma
Background: Multiple myeloma (MM) is a clonal plasma cell neoplasm characterized by proliferation of neoplastic plasma cells in bone marrow (BM). So far, it is an incurable disease and th...
A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies
Rationale: ImMucin was shown to be able to induce a robust cellular immune response mediated via both CD4+ and CD8+ T lymphocytes and therefore, could potentially be more effective in the...
Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma
PRIMARY STUDY OBJECTIVES - To evaluate the efficacy of the combination of clarithromycin (Biaxin®), lenalidomide (Revlimid™), and dexamethasone (Decadron®) as an induction the...
Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma
PRIMARY STUDY OBJECTIVES - To evaluate the efficacy of the combination of bortezomib, dexamethasone, with and without DOXIL, followed by high-dose cyclophosphamide as a therapy fo...
Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma
This study is for patients with newly diagnosed or relapsed multiple myeloma. The main purpose of this study is to see how their disease responds to consolidation treatment (treatment aim...
Background: In some studies, thalidomide in combination with chemotherapy has been shown to be effective in patients with relapsed or refractory multiple myeloma (MM). In this study, the r...
PubMed Articles
8p21.3 deletion was recently characterized in B cell lymphoma suggesting that TRAIL-R1 and TRAIL-R2 may be the target of the deletion and act as dosage-dependent tumor suppressor genes. As multiple my...
To study the molecular mechanism of suppressed growth caused by Trichinella spiralis, an SP2/0 myeloma model was established using parasite-infected Balb/c mice. Suppression subtractive hybridization...
To obtain novel antigen genes for use as an anti-tumor vaccine, a Trichinella spiralis cDNA expression library was constructed from muscle larvae RNA and screened with sera from Balb/C mice injected w...
BACKGROUND: The goal of this large prospective population-based study was to examine the association between depressive symptoms and all-cause mortality among cancer survivors up to 10 years post-dia...
ALT-803, a complex of an interleukin (IL)-15 superagonist mutant and a dimeric IL-15 receptor αSu/Fc fusion protein, was found to exhibit significantly stronger in vivo biologic activity on NK and T...
Bisphosphonate-associated osteonecrosis of the external auditory canal.
Background: Osteonecrosis is a benign condition characterised by necrotic exposed bone, and is associated with bisphosphonate use. Osteonecrosis of the external auditory canal is rare, with only a few...
Several cytogenetic abnormalities are associated with poor outcomes in multiple myeloma (MM). We prospectively analyzed the impact of cytogenetic abnormalities on outcomes during the phase 2 PX-171-00...
We performed a molecular study aimed at identifying a gene expression profile (GEP) signature predictive of attainment of at least near complete response (CR) to thalidomide-dexamethasone (TD) as indu...
Videos
Myeloma for beginners - Understanding myeloma
Dr Graham Jackson, Consultant Haematologist and Senior Lecturer, Royal Victoria Hospital, Newcastle upon Tyne, answers questions to help patients, families a...
Medical and Biotech [MESH] Definitions
Proto-oncogene Proteins C-maf
Maf proto-oncogene protein is the major cellular homolog of the V-MAF ONCOGENE PROTEIN. It was the first of the mammalian MAF TRANSCRIPTION FACTORS identified, and it is induced in activated T-LYMPHOCYTES and regulates GENETIC TRANSCRIPTION of INTERLEUKIN-4. c-maf is frequently translocated to an immunoglobulin locus in MULTIPLE MYELOMA.
Pyroglobulins
Atypical gamma immunoglobulins characterized by their irreversible heat denaturation at 56-degrees C. Pyroprecipitation is inhibited at pH below 3 and above 9. The presence of pyroglobulins in the serum is the cause of pyroglobulinemia. They are frequently present in multiple myeloma and the pyroglobulin precipitate binds complement, reacts with rheumatoid factor, produces passive cutaneous anaphylaxis, generalized passive anaphylaxis and passive Arthus-type phenomena.
Staphylococcal Protein A
A protein present in the cell wall of most Staphylococcus aureus strains. The protein selectively binds to the Fc region of human normal and myeloma-derived IMMUNOGLOBULIN G. It elicits antibody activity and may cause hypersensitivity reactions due to histamine release; has also been used as cell surface antigen marker and in the clinical assessment of B lymphocyte function.
Hla-c Antigens
Class I human histocompatibility (HLA) antigens encoded by a small cluster of structural genes at the C locus on chromosome 6. They have significantly lower immunogenicity than the HLA-A and -B determinants and are therefore of minor importance in donor/recipient crossmatching. Their primary role is their high-risk association with certain disease manifestations (e.g., spondylarthritis, psoriasis, multiple myeloma).
Muromonab-cd3
Anti-CD3 monoclonal antibody that exerts immunosuppressive effects by inducing peripheral T-cell depletion and modulation of the T-cell receptor complex (CD3/Ti). This biochemically purified IMMUNOGLOBULIN G is obtained through the fusion of mouse myeloma cells to lymphocytes from immunized animals to produce hybridomas that secrete specific antibodies to the T3 (CD3) antigens of human T-lymphocytes. It is often used as an IMMUNOSUPPRESSIVE AGENTS in TRANSPLANTATION.
